Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria

被引:12
作者
Demetrio Pablo, Rosalia [1 ]
Munoz, Pedro [2 ]
Lopez-Hoyos, Marcos [4 ]
Calvo, Vanesa [3 ]
Riancho, Leyre [3 ]
Manuel Martinez-Taboada, Victor [3 ]
机构
[1] Univ Cantabria, Fac Med, Inst Invest Sanitaria Valdecilla IDIVAL, Hosp Univ Marques De Valdecilla,Serv Oftalmol, Santander, Spain
[2] Univ Cantabria, Fac Med,Hosp Univ Marques De Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Gerencia Atenc Primaria,Serv Cantabro Salud, Santander, Spain
[3] Univ Cantabria, Fac Med, Inst Invest Sanitaria Valdecilla IDIVAL, Serv Reumatol,Hosp Univ Marques De Valdecilla, Santander, Spain
[4] Univ Cantabria, Fac Med, Inst Invest Sanitaria Valdecilla IDIVAL, Hosp Univ Marques De Valdecilla,Inmunol, Santander, Spain
来源
MEDICINA CLINICA | 2017年 / 148卷 / 09期
关键词
Antiphospholipid syndrome; Thrombocytopenia; Antiphospholipid antibodies; PRELIMINARY CLASSIFICATION CRITERIA; INTERNATIONAL CONSENSUS STATEMENT; FOLLOW-UP; MANIFESTATIONS; PURPURA; ASSOCIATION; DIAGNOSIS;
D O I
10.1016/j.medcli.2016.11.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The antiphospholipid syndrome (APS) is an acquired immune disorder defined by the presence of thrombosis (arterial and/or venous) and/or pregnancy morbidity along with the presence of positive antiphospholipid antibodies (aPL). There is a clear relationship between aPL and some events not included in the clinical criteria, including haematologic. Objectives: a) to study the probability of developing clinical APS in patients with positive aPL and thrombopenia; b) to identify potential risk factors for thrombosis, and c) to study the association between thrombocytopenia and aPL. Methods: A retrospective study of 138 patients with positive aPL without fulfilling clinical criteria for APS. Thrombocytopenia was defined as a platelet count <= 100,000/mu l. Patients with other causes of thrombocytopenia were excluded. Results: Seventeen of the 138 (12%) patients in the study had thrombocytopenia. The mean platelet count was 60,000/mu l. The risk of developing thrombocytopenia was higher in smokers (OR 2.8; P = .044), in those with lupus anticoagulant (OR 13.5; P < .001) and those with higher burden of aPL (OR 50.8; P < .001). After a mean follow-up of 146 +/- 60.3 months, 5 patients with thrombocytopenia (29.4%) developed thrombosis. Conclusions: In our series, the incidence of thrombocytopenia is 12%. aPL-positive patients who develop thrombocytopenia have a potential risk of developing thrombosis. Tobacco could be a risk factor for thrombocytopenia. Autoantibodies load is a risk factor for the development of thrombocytopenia. (C) 2016 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:394 / 400
页数:7
相关论文
共 31 条
[1]   PRELIMINARY CLASSIFICATION CRITERIA FOR THE ANTIPHOSPHOLIPID SYNDROME WITHIN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ALARCONSEGOVIA, D ;
PEREZVAZQUEZ, ME ;
VILLA, AR ;
DRENKARD, C ;
CABIEDES, J .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1992, 21 (05) :275-286
[2]   Anti phospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS) [J].
Bidot, Carlos J. ;
Jy, Wenche ;
Horstman, Lawrence L. ;
Ahn, Eugene R. ;
Yaniz, Miriam ;
Ahn, Yeon S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (06) :391-396
[3]   Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission [J].
Bidot, CJ ;
Jy, W ;
Horstman, LL ;
Ahn, ER ;
Jimenez, JJ ;
Yaniz, M ;
Lander, G ;
Ahn, YS .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (03) :366-372
[4]   Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Shoenfeld, Y ;
Camps, MT ;
Jacobsen, S ;
Lakos, G ;
Tincani, A ;
Kontopoulou-Griva, I ;
Galeazzi, M ;
Meroni, PL ;
Derksen, RHWM ;
de Groot, PG ;
Gromnica-Ihle, E ;
Baleva, M ;
Mosca, M ;
Bombardieri, S ;
Houssiau, F ;
Gris, JC ;
Quéré, I ;
Hachulla, E ;
Vasconcelos, C ;
Roch, B ;
Fernández-Nebro, A ;
Boffa, MC ;
Hughes, GRV ;
Ingelmo, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027
[5]   Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations [J].
Cervera, R. ;
Tektonidou, M. G. ;
Espinosa, G. ;
Cabral, A. R. ;
Gonzalez, E. B. ;
Erkan, D. ;
Vadya, S. ;
Adrogue, H. E. ;
Solomon, M. ;
Zandman-Goddard, G. ;
Shoenfeld, Y. .
LUPUS, 2011, 20 (02) :174-181
[6]   The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe [J].
Cervera, R. ;
Boffa, M-C ;
Khamashta, M. A. ;
Hughes, G. R. V. .
LUPUS, 2009, 18 (10) :889-893
[7]   Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study [J].
Comellas-Kirkerup, Lucia ;
Hernandez-Molina, Gabriela ;
Cabral, Antonio R. .
BLOOD, 2010, 116 (16) :3058-3063
[8]   Thrombocytopenia in the antiphospholipid syndrome [J].
Cuadrado, MJ ;
Mujic, F ;
Munoz, E ;
Khamashta, MA ;
Hughes, GRV .
ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (03) :194-196
[9]  
Dasanu Constantin A, 2011, Conn Med, V75, P281
[10]  
Demetrio R, 2016, EULAR ABSTRACT ARCH